The concept of microsampling and particularly the dried blood spot methodology has been widely known to the scientific community for considerable time. Yet, there is no formal standard approach available to date for the pharmaceutical community to benefit from, in its regulatory interactions. This article discusses the various aspects of these issues and provides a framework within which a standard set of procedures can be adopted.